ATOPIC DERMATITIS | PFIZER B7451014 | PHASE III

Status: FULLY RECRUITED

Drug: PF-04965842

Timeline: 56 weeks

Detailed Description

This trial will evaluate and compare the maintenance of effect of two doses of PF-04965842 (200 mg and 100mg once daily) and placebo in subjects aged 12 and above with moderate to severe atopic dermatitis who respond to an initial open-label run-in treatment of 200mg.

Inclusion

• Informed consent
• Male or Female
• Age 12 years and older
• Body Weight at baseline >=40 kg
• Diagnosis of AD for more than 1 year
• Documented recent history of inadequate response to treatment with topical medications for at least 4 weeks or need for systemic therapies

Exclusions

• Current participation in any other interventional trial
• Previous treatment with any JAK inhibitors
• Significant medical history
• Female subjects who are pregnant or lactating

If you’re interested in participating, please SEND US AN EMAIL AND/OR CONTACT US and our research team will be in touch.